Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases

[Image: see text] Visceral leishmaniasis is responsible for up to 30,000 deaths every year. Current treatments have shortcomings that include toxicity and variable efficacy across endemic regions. Previously, we reported the discovery of GNF6702, a selective inhibitor of the kinetoplastid proteasome...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Med Chem
Main Authors: Nagle, Advait, Biggart, Agnes, Be, Celine, Srinivas, Honnappa, Hein, Andreas, Caridha, Diana, Sciotti, Richard J., Pybus, Brandon, Kreishman-Deitrick, Mara, Bursulaya, Badry, Lai, Yin H., Gao, Mu-Yun, Liang, Fang, Mathison, Casey J. N., Liu, Xiaodong, Yeh, Vince, Smith, Jeffrey, Lerario, Isabelle, Xie, Yongping, Chianelli, Donatella, Gibney, Michael, Berman, Ashley, Chen, Yen-Liang, Jiricek, Jan, Davis, Lauren C., Liu, Xianzhong, Ballard, Jaime, Khare, Shilpi, Eggimann, Fabian Kurt, Luneau, Alexandre, Groessl, Todd, Shapiro, Michael, Richmond, Wendy, Johnson, Kevin, Rudewicz, Patrick J., Rao, Srinivasa P. S., Thompson, Christopher, Tuntland, Tove, Spraggon, Glen, Glynne, Richard J., Supek, Frantisek, Wiesmann, Christian, Molteni, Valentina
Formato: Artigo
Idioma:Inglês
Publicado em: American Chemical Society 2020
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7549094/
https://ncbi.nlm.nih.gov/pubmed/32667203
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.jmedchem.0c00499
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados